Travere Therapeutics Inc (NASDAQ: TVTX) is 89.79% higher on its value in year-to-date trading and has touched a low of $7.93 and a high of $25.29 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TVTX stock was last observed hovering at around $16.33 in the last trading session, with the day’s gains setting it 0.22%.
Currently trading at $16.55, the stock is 11.01% and -0.80% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.42 million and changing 1.35% at the moment leaves the stock -7.71% off its SMA200. TVTX registered -4.99% loss for a year compared to 6-month loss of -11.54%. The firm has a 50-day simple moving average (SMA 50) of $16.6831 and a 200-day simple moving average (SMA200) of $17.932726.
The stock witnessed a 11.00% gain in the last 1 month and extending the period to 3 months gives it a 16.96%, and is 11.52% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.13% over the week and 4.63% over the month.
Travere Therapeutics Inc (TVTX) has around 385 employees, a market worth around $1.47B and $273.53M in sales. Fwd P/E is 33.14. Profit margin for the company is -82.88%. Distance from 52-week low is 108.67% and -34.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.14%).
The EPS is expected to grow by 73.28% this year
300.0 institutions hold shares in Travere Therapeutics Inc (TVTX), with institutional investors hold 114.15% of the company’s shares. The shares outstanding are 88.79M, and float is at 87.44M with Short Float at 11.81%. Institutions hold 113.30% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.64 million shares valued at $62.84 million. The investor’s holdings represent 9.8642 of the TVTX Shares outstanding. As of 2024-06-30, the second largest holder is ARMISTICE CAPITAL, LLC with 7.5 million shares valued at $61.65 million to account for 9.6774 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 7.37 million shares representing 9.5096 and valued at over $60.58 million, while VANGUARD GROUP INC holds 8.5416 of the shares totaling 6.62 million with a market value of $54.41 million.
Travere Therapeutics Inc (TVTX) Insider Activity
The most recent transaction is an insider sale by Inrig Jula, the company’s CHIEF MEDICAL OFFICER. SEC filings show that Inrig Jula sold 815 shares of the company’s common stock on Jul 01 ’25 at a price of $14.65 per share for a total of $11940.0. Following the sale, the insider now owns 88787.0 shares.
Travere Therapeutics Inc disclosed in a document filed with the SEC on May 05 ’25 that Cline Christopher R. (CHIEF FINANCIAL OFFICER) sold a total of 1,784 shares of the company’s common stock. The trade occurred on May 05 ’25 and was made at $21.05 per share for $37553.0. Following the transaction, the insider now directly holds 93126.0 shares of the TVTX stock.
Still, SEC filings show that on May 05 ’25, Dube Eric M (CHIEF EXECUTIVE OFFICER) disposed off 18,924 shares at an average price of $21.05 for $0.4 million. The insider now directly holds 419,173 shares of Travere Therapeutics Inc (TVTX).
